Marina Kosinova

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma

Martin Dreyling, Armando Santoro, Luigina Mollica et al. · Journal of Clinical Oncology · 2017 · 398 citations

Medicine, Oncology, Pharmacology +13

Long‐term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2‐year follow‐up of the CHRONOS‐1 study

Martin Dreyling, Armando Santoro, Luigina Mollica et al. · American Journal of Hematology · 2019 · 172 citations · Full text

Medicine, Oncology, Pharmacology +12

Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A

Johnny Mahlangu, Kazimierz Kuliczkowski, Faraizah Abdul Karim et al. · Blood · 2016 · 86 citations · Full text

Medicine, Hematology, Transfusion Medicine +3

Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety

Johnny Mahlangu, Howard Levy, Marina Kosinova et al. · Research and Practice in Thrombosis and Haemostasis · 2021 · 17 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Long-Term Efficacy and Safety from the Copanlisib CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma

Martin Dreyling, Armando Santoro, Luigina Mollica et al. · Blood · 2018 · 12 citations

Medicine, Oncology, Pharmacotherapy +16